Literature DB >> 19795125

[BRCA1- and BRCA2- associated breast carcinomas].

P Ahrens1, H H Kreipe.   

Abstract

Breast cancers with a genetic BRCA1-/BRCA2 background differ from each other and sporadic cases. A specific pathological surrogate marker, however, does not exist. In this study the results of a German reference centre are reported. BRCA1 associated cancers are predominantly high grade (G3), triple negative, highly proliferative (median Ki-67 55%) and only exceptionally accompanied by lobular intraepithelial neoplasia. Cancers with a BRCA2 germ line mutation are less frequent and resemble sporadic cases with a comparably higher proliferative activity and a lack of Her2 overexpression.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19795125     DOI： 10.1007/s00292-009-1223-3

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  6 in total

1.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Authors:  Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

2.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

Authors: 
Journal:  Lancet       Date:  1997-05-24       Impact factor: 79.321

Review 3.  The search for low-penetrance cancer susceptibility alleles.

Authors:  Richard S Houlston; Julian Peto
Journal:  Oncogene       Date:  2004-08-23       Impact factor: 9.867

4.  Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

Authors:  S R Lakhani; J Jacquemier; J P Sloane; B A Gusterson; T J Anderson; M J van de Vijver; L M Farid; D Venter; A Antoniou; A Storfer-Isser; E Smyth; C M Steel; N Haites; R J Scott; D Goldgar; S Neuhausen; P A Daly; W Ormiston; R McManus; S Scherneck; B A Ponder; D Ford; J Peto; D Stoppa-Lyonnet; Y J Bignon; J P Struewing; N K Spurr; D T Bishop; J G Klijn; P Devilee; C J Cornelisse; C Lasset; G Lenoir; R B Barkardottir; V Egilsson; U Hamann; J Chang-Claude; H Sobol; B Weber; M R Stratton; D F Easton
Journal:  J Natl Cancer Inst       Date:  1998-08-05       Impact factor: 13.506

Review 5.  Breast cancer susceptibility: current knowledge and implications for genetic counselling.

Authors:  Tim Ripperger; Dorothea Gadzicki; Alfons Meindl; Brigitte Schlegelberger
Journal:  Eur J Hum Genet       Date:  2008-12-17       Impact factor: 4.246

6.  Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients.

Authors:  T Byrski; T Huzarski; R Dent; J Gronwald; D Zuziak; C Cybulski; J Kladny; B Gorski; J Lubinski; S A Narod
Journal:  Breast Cancer Res Treat       Date:  2008-07-23       Impact factor: 4.872
  6 in total
  2 in total

Review 1.  [Genes beyond BRCA1 and BRCA2 for hereditary breast cancer].

Authors:  Katharina Simon; Jochen B Geigl; Gunda Pristauz
Journal:  Wien Med Wochenschr       Date:  2010-11

2.  Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.

Authors:  Dorothea Gadzicki; D Gareth Evans; Hilary Harris; Claire Julian-Reynier; Irmgard Nippert; Jörg Schmidtke; Aad Tibben; Christi J van Asperen; Brigitte Schlegelberger
Journal:  J Community Genet       Date:  2011-03-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.